Implementation of pharmacophore-based 3D QSAR model and scaffold analysis in order to excavate pristine ALK inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Medicinal Chemistry Research"
DOI: 10.1007/s00044-019-02410-9
Abstract: The utilisation of anaplastic lymphoma kinase (ALK) inhibitors has unveiled a magnificent clinical activity in ALK-positive non-small cell lung cancer (NSCLC), as well as against the sanctuary site of CNS in selected patients. However, the… read more here.
Keywords: alk inhibitors; order; alk; analysis ... See more keywords
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Sign Up to like & getrecommendations! Published in 2018 at "Biochimie"
DOI: 10.1016/j.biochi.2018.07.018
Abstract: Multiple laboratory evidences indicate that distinct variants of ALK translocations differ in their biochemical properties and responsiveness to ALK tyrosine kinase inhibitors (TKIs). These data are supported by some clinical studies, which showed improved responses… read more here.
Keywords: alk inhibitors; alk fusion; alk; fusion variants ... See more keywords
Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer genetics"
DOI: 10.1016/j.cancergen.2019.12.003
Abstract: ALK FISH assay guides clinical decision to initiate therapy with ALK inhibitors in patients with stage IV non-small cells lung cancer (NSCLC). In this single institution retrospective study, we investigated the association between the strength… read more here.
Keywords: alk inhibitors; alk fish; alk; lung cancer ... See more keywords
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2018.11.004
Abstract: INTRODUCTION Oral tyrosine kinase inhibitors targeting the chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) in non-small cell lung cancer (NSCLC) were associated with superior clinical outcome. Tyrosine Kinase inhibitors (TKIs) are known to… read more here.
Keywords: alk inhibitors; treatment; systematic review; safety ... See more keywords
PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.11.002
Abstract: OBJECTIVES In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement identifies a subgroup of patients who are sensitive to ALK tyrosine kinase inhibitors (TKIs). ALK fusion is extremely rare in small-cell lung cancer… read more here.
Keywords: alk inhibitors; alk fusion; alk; lung cancer ... See more keywords
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.04.011
Abstract: OBJECTIVES No overall survival (OS) benefit has been reported from a mature randomized trial with the use of ALK inhibitors. We conducted a systematic review and meta-analysis to assess the efficacy of ALK inhibitors compared… read more here.
Keywords: alk inhibitors; alk alk; alk; meta analysis ... See more keywords
Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design
Sign Up to like & getrecommendations! Published in 2020 at "ACS Omega"
DOI: 10.1021/acsomega.0c04900
Abstract: Fragment screening is frequently used for hit identification. However, there was no report starting from a small fragment for the development of an anaplastic lymphoma kinase (ALK) inhibitor, despite the number of ALK inhibitors reported.… read more here.
Keywords: alk inhibitors; highly selective; alk; structure based ... See more keywords
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Nature Medicine"
DOI: 10.1038/nm.4497
Abstract: Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approximately half harbor resistance mutations… read more here.
Keywords: alk inhibitors; alk; rearranged non; inhibition ... See more keywords
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of medicine"
DOI: 10.1080/07853890.2023.2187077
Abstract: Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer constitute an extremely difficult clinical problem, and their occurrence is associated with a poor prognosis. Due to the existence of the… read more here.
Keywords: alk inhibitors; nsclc patients; inhibitors treatment; cns metastases ... See more keywords
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2018.1527902
Abstract: ABSTRACT Introduction: The medical treatment of non-small cell lung cancer (NSCLC) has radically changed over the last 10 years thanks to new molecular-targeted drugs able to act on biological mechanisms involved in tumor development. One… read more here.
Keywords: alk inhibitors; alk; treatment; generation ... See more keywords
Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?
Sign Up to like & getrecommendations! Published in 2017 at "Cell Cycle"
DOI: 10.1080/15384101.2016.1247568
Abstract: The approval of multitargeted anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has been a success story for the management of advanced non-small-cell lung cancers (NSCLCs) over the last half a decade, with the 1st… read more here.
Keywords: alk inhibitors; resistance alk; alk; kinase ... See more keywords